A current study [66] found that chemoresistant NSCLC patients had upregulated Notch3 expression, which was related to poor prognosis and had augmented levels of CSC markers, ALDH1A1 and CD44, correlating with Notch3 expression in lung cancer biopsies. This evidence concerns the gene NOTCH3 and lung cancer.